Miruvor
Sign up
The short answer

What studies of erythromycin found

3papers on erythromycin
22people in 1 study testing erythromycin alone
0randomised trials, the strongest kind of study

At a glance, by condition

ME/CFS: D Little or no difference

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 of 4 findings are D.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with erythromycin for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Erythromycin · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Sleep1 study · 22 people took erythromycin Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).

Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days

Sleep improved.

The evidence is very uncertain about the effect of erythromycin on sleep in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)
See the 1 study
  1. Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)

    People in the study
    70 in the study · 22 with outcome data
    Dose
    400 mg b.d, at Day 8 for 6 days
    Outcome
    subjective sleep quality sleep diary
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 22 people took erythromycin Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).

Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days

No clear change in fatigue.

The evidence is very uncertain about the effect of erythromycin on fatigue in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): fatigue, no clear difference.

Shown, not counted: erythromycin was given together with other treatments.

See the 1 study
  1. Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)

    People in the study
    70 in the study · 22 with outcome data
    Dose
    400 mg b.d, at Day 8 for 6 days
    Outcome
    Chalder Fatigue Scale
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 22 people took erythromycin Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).

Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days

No clear change in low mood or anxiety.

The evidence is very uncertain about the effect of erythromycin on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)
See the 1 study
  1. Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)

    People in the study
    70 in the study · 22 with outcome data
    Dose
    400 mg b.d, at Day 8 for 6 days
    Outcome
    POMS subscales Profile of Mood States Short Form
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 22 people took erythromycin Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).

Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days

No clear change in overall symptoms.

The evidence is very uncertain about the effect of erythromycin on overall symptoms in ME/CFS. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): self-reported total symptoms (SSH), better.

Shown, not counted: erythromycin was given together with other treatments.

See the 1 study
  1. Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)

    People in the study
    70 in the study · 22 with outcome data
    Dose
    400 mg b.d, at Day 8 for 6 days
    Outcome
    CFS symptoms total ratings score Symptoms Severity Profile
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of erythromycin given together with other treatments looked at. Shown, not graded: they can’t tell what erythromycin did alone.

Cognition (brain fog) ME/CFS

Combination: Erythromycin + Probiotics and fermented foods44 in the study

Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): cognitive flexibility, better.

Shown, not counted: erythromycin was given together with other treatments.

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    400 mg at the start

  2. 2Top dose

    Most often 400 mg (2 of 2 studies)

Doses across 2 studies

400 to 400 mg.

Each study’s dose, as printed

All papers

  1. The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). I. A Pilot study of the new vitamin C infusion treatment with a volunteer CFS patient.1996 · compared with another group
    Summary

    This pilot study followed a single male volunteer with chronic fatigue syndrome (CFS) from August 1995 to May 1996. The paper does not report where the patient was from or how he was selected. An annex-free vitamin C drip infusion set (the old set) and a dehydroepiandrosterone-annexed vitamin C infusion set (the new set) were prepared. The patient also received oral erythromycin and chloramphenico; the abstract does not give doses, schedules or durations for the infusion sets or antibiotics. The report describes the first, second and 3rd stages of disease. From August to October 1995, the old infusion together with short-term antibiotics was found effective for control of pneumonia. From November 1995 to January 1996, signs of pneumonia recurrence became eminent despite moderate frequency of the old treatment and stepwise prolongation of antibiotics. From February to May 1996, alternating the old and new infusions together with long-term antibiotics led to substantial extinction of pneumonia signs (leucocytosis, tachycardia etc). An immunological survey of lymphocyte subsets including NK cell percent failed to find a coherent change. Side effects and withdrawals were not reported. No enrolled or analysed counts, and no comparison-group numbers, are reported. The authors state no limitations in the abstract.

  2. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.2018 · combination: given with other treatments · 44 in the study
    Summary

    This open-label, non-randomised pilot with repeated measures and no comparison group examined an antibiotic/probiotic intervention in 44 adult ME/CFS patients (27 females) from one specialist medical clinic with Streptococcus viable counts above 3.00 × 105 cfu/g. Treatment was Erythromycin 400 mg twice daily during weeks 2 and 4, alternating with Pro4-50 d-lactate free multistrain probiotic two capsules daily during weeks 3 and 5, within a 4-week treatment protocol across 6 weeks. Outcomes included sleep, mood, cognition, fatigue, total symptoms, microbiota and urine d:l lactate ratio. Actigraphic sleep efficiency did not change (M = 83.94 to M = 83.80; partial eta squared = .03, p < .297). RVP A′ improved from M = .91 to M = .94 (partial eta squared = .53, p < .001), and SSH total symptoms reduced from M = 28.42 to M = 22.76 (partial eta squared = .29, p = .001). Mood, fatigue and urine d:l lactate ratio remained similar across time. Sex-time interactions revealed no large effects and did not support a sex-specific response. Six unexpected adverse events were reported from five participants; one discontinued all treatment after the first antibiotic dose. The authors state the open-label design and practice effects limit interpretation.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime